ALEC - NASDAQ
Alector, Inc.
$1.77
-6.1%Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
At a Glance
Live Snapshotalec
Selling, General and Administrative Expenses
Last Annual Value
53.99M
3-Year CAGR
-4%
5-Year CAGR
-2%
10-Year CAGR
40%
Alector, Inc. Competitors Analysis of Selling, General and Administrative Expenses
| Company | Selling, General and Administrative Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Alector, Inc. NASDAQ:ALEC | 53.99M | -1.6% | -0.4% | 39.9% | |
 Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP | 15.21M | 3.0% | -5.7% | 8.9% | |
 Fate Therapeutics, Inc. NASDAQ:FATE | 46.52M | -21.7% | -4.1% | 16.7% | |
 Vor Biopharma Inc. NASDAQ:VOR | 50.11M | 16.5% | 18.5% | N/A | |
 Opus Genetics, Inc. NASDAQ:IRD | 21.98M | 22.5% | 22.0% | N/A | |
 PepGen Inc. NASDAQ:PEPG | 22.57M | 10.7% | 22.7% | N/A | |
 Annexon, Inc. NASDAQ:ANNX | 31.71M | 4.2% | 0.7% | N/A | |
 Capricor Therapeutics, Inc. NASDAQ:CAPR | 23.69M | 22.7% | 25.5% | 17.0% | |
 Kyverna Therapeutics, Inc. NASDAQ:KYTX | 36.11M | 42.5% | 42.5% | N/A | |
 Larimar Therapeutics, Inc. NASDAQ:LRMR | 18.27M | 9.1% | 8.6% | 0.6% | |
 Lexeo Therapeutics, Inc. Common Stock NASDAQ:LXEO | 45.46M | 43.5% | 44.7% | N/A |
Alector, Inc. Fair Value Envelope
Related Guides
Continue your ALEC research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.